Treatment effect of capecitabine and docetaxel or docetaxel alone byoestrogen receptor status in patients with metastatic breast cancer: Results of an exploratory analysis

S. Glück, C. Russell, J. O'Shaughnessy, E. F. McKenna, S. Hu, D. Odom, J. L. Blum

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

We investigated treatment effects by oestrogen receptor (ER) status among women with metastatic breast cancer (MBC) receiving capecitabine (C) plus docetaxel (D) or D alone in a randomised phase III trial. Data were retrospectively analysed from patients whose disease had recurred following (neo)adjuvant anthracyclines. ER status was identified in 356/506 patients. In patients with ER-positive tumours, median overall survival from enrolment was 17.7 months with CD versus 12.5 months with D (hazard ratio [HR] 0.65, 95% confidence interval [CI]: 0.47-0.89; P=0.007) and median time to progression (TTP) was 6.8 and 5.4 months, respectively (HR 0.62, 95% CI: 0.46-0.84; P=0.002). For patients with ER-negative tumours, significantly longer TTP was seen with CD (5.2 versus 3.5 months; HR 0.73, 95% CI: 0.53-0.98; P=0.038). Whether there is an additional C to D treatment benefit in ER-positive versus ER-negative MBC requires further evaluation.

Original languageEnglish (US)
Pages (from-to)1087-1093
Number of pages7
JournalBreast
Volume22
Issue number6
DOIs
StatePublished - Dec 2013

Keywords

  • Capecitabine
  • Docetaxel
  • Exploratory analysis
  • Hormone receptor status
  • Metastatic breast cancer
  • Survival

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Treatment effect of capecitabine and docetaxel or docetaxel alone byoestrogen receptor status in patients with metastatic breast cancer: Results of an exploratory analysis'. Together they form a unique fingerprint.

  • Cite this